Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Head & Neck 1

Conditions

Leukemia, Myeloid, Acute 13Myelodysplastic Syndromes 5Advanced Solid Tumors 5Advanced Solid Tumour 4Myeloproliferative Disorders 3Leukemia, Myelomonocytic, Chronic 3Small Cell Lung Carcinoma 2Recurrence 2Multiple Myeloma 2Carcinoma, Non-Small-Cell Lung 2Advanced Solid Tumor 2Advanced Lung Cancer 2Unresectable Locally Recurrent Breast Cancer 1Squamous Cell Carcinoma of Head and Neck 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Non-small Lung Cancer 1Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Multiple Sclerosis 1Metastatic Solid Tumors 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Monocytic, Acute 1Leukemia, Biphenotypic, Acute 1Idiopathic Pulmonary Fibrosis 1Digestive System Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Depression 1

Interventions

Cyclophosphamide 9fludarabine 7Dexamethasone 7pomalidomide 6Rituximab 6pembrolizumab 5selinexor 4obinutuzumab 4glofitamab 4Lenalidomide 4daratumumab 3belantamab mafodotin 3Temozolomide 3Gemcitabine 3Etoposide 3Bortezomib 3zanubrutinib 2venetoclax 2tocilizumab 2fludarabine phosphate 2enzalutamide 2cemiplimab 2carfilzomib 2abemaciclib 2PF06821497 2Mesna 2Lisaftoclax 2Injections 2Immunotherapy, Adoptive 2Granulocyte Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × Injections × 30 days × Clear all
NCT05564650 2026-05-19

Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Thomas Jefferson University

Phase 1 Completed
6 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT05294172 2026-05-08

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 3 Active not recruiting
295 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡